Provided by Tiger Trade Technology Pte. Ltd.

Celcuity Inc

114.22
+3.453.11%
Post-market: 114.220.00000.00%18:59 EDT
Volume:434.74K
Turnover:49.44M
Market Cap:5.29B
PE:-31.11
High:116.11
Open:110.79
Low:110.79
Close:110.77
52wk High:120.32
52wk Low:7.58
Shares:46.27M
Float Shares:22.54M
Volume Ratio:0.52
T/O Rate:1.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6721
EPS(LYR):-2.8335
ROE:-122.04%
ROA:-26.60%
PB:45.19
PE(LYR):-40.31

Loading ...

Assessing Celcuity (CELC) Valuation After Wells Fargo Coverage And Key FDA NDA Review Progress

Simply Wall St.
·
Jan 12

BRIEF-Celcuity Files For Mixed Shelf Size Not Disclosed - SEC Filing

Reuters
·
Jan 10

Celcuity Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
Jan 10

Did Gedatolisib’s Phase 3 PFS and Tolerability Data Just Shift Celcuity’s (CELC) Investment Narrative?

Simply Wall St.
·
Dec 16, 2025

Celcuity Reports Positive Phase 3 Results for Gedatolisib in Advanced Breast Cancer Trial

Reuters
·
Dec 12, 2025

Celcuity Presents Updated Results From the Pik3CA Wild-Type Cohort of the Phase 3 Viktoria-1 Trial at the 2025 San Antonio Breast Cancer Symposium

THOMSON REUTERS
·
Dec 12, 2025

Is Celcuity’s Huge 2025 Rally Justified by Its Long Term Cash Flow Potential?

Simply Wall St.
·
Dec 11, 2025

Celcuity Inc. Director Richard E. Buller Reports Sale of Common Shares

Reuters
·
Dec 10, 2025

Muling, Heilongjiang: Flax Weaving a Prosperous Industry

Deep News
·
Dec 08, 2025

Celcuity Is Maintained at Buy by Jefferies

Dow Jones
·
Dec 02, 2025

U.S. RESEARCH ROUNDUP- Green Brick Partners, Pultegroup, Toll Brothers

Reuters
·
Dec 02, 2025

Celcuity Announces Updated Phase 3 VIKTORIA-1 Trial Results for Gedatolisib in HR+/HER2- Advanced Breast Cancer

Reuters
·
Nov 27, 2025

Celcuity Inc. to Present at Evercore Healthcare Conference

Reuters
·
Nov 26, 2025

Celcuity Inc. Director David Dalvey Reports Sale of Common Shares

Reuters
·
Nov 25, 2025

Celcuity Director Richard E. Buller Reports Disposal of Common Shares

Reuters
·
Nov 22, 2025

Biotech Reawakens: Policy Clarity, Breakthrough Data and a Surge in M&A

LiveWire
·
Nov 21, 2025

Celcuity Q3 Adjusted EPS USD -0.78 Vs. IBES Estimate USD -1.02

Reuters
·
Nov 20, 2025

Celcuity Initiated at Outperform by Wolfe Research

Dow Jones
·
Nov 19, 2025

Celcuity initiated with an Outperform at Wolfe Research

TIPRANKS
·
Nov 18, 2025

Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in Hr+/Her2-/Pik3CA Wild-Type Advanced Breast Cancer

THOMSON REUTERS
·
Nov 18, 2025